MedTrace Logo

Understanding and Restoring Dopaminergic Function in Fibromyalgia Patients

NCT04451564 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-01-13

No results posted yet for this study

Summary

Fibromyalgia (FM) is a very prevalent and debilitating chronic pain disorder that is difficult to treat. Mindfulness-based techniques are regarded as a very promising approach for the treatment of chronic pain and in particular FM. The Mindfulness-Oriented Recovery Enhancement (MORE) intervention, a mindfulness-based group intervention, has shown beneficial effects in opioid-treated chronic pain patients, including reduced pain severity, functional interference, and opioid dosing, by restoring neurophysiological and behavioral responses to reward. First evidence for a hypodopaminergic state and impaired reward processing in FM have been reported. However, little is known about its impact on dopamine (DA) function and in particular with regard to DA responses to monetary reward in FM. The aim of the present study protocol is to evaluate if MORE is able to restore the DA function in FM patients, in particular with regard to the DA responses to reward, and to reduce pain and mood complaints in FM.

Conditions

  • Fibromyalgia

Interventions

BEHAVIORAL

Mindfulness oriented recovery enhancement

8- week psychological program based on mindfulness techniques

Sponsors & Collaborators

  • University of Lausanne

    collaborator OTHER

  • University of Zurich

    collaborator OTHER

  • University of Utah

    collaborator OTHER

  • University of Fribourg

    lead OTHER

Principal Investigators

  • Chantal o Martin Sölch, PhD · University of Fribourg

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2023-01-31
Completion
2024-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04451564 on ClinicalTrials.gov